Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes
- PMID: 16942126
- DOI: 10.2165/00019053-200624090-00009
Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes
Comment on
-
A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies.Pharmacoeconomics. 2006;24 Suppl 1:5-19. doi: 10.2165/00019053-200624001-00002. Pharmacoeconomics. 2006. PMID: 16800159 Review.
-
Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.Pharmacoeconomics. 2006;24 Suppl 1:21-34. doi: 10.2165/00019053-200624001-00003. Pharmacoeconomics. 2006. PMID: 16800160 Review.
-
Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.Pharmacoeconomics. 2006;24 Suppl 1:35-48. doi: 10.2165/00019053-200624001-00004. Pharmacoeconomics. 2006. PMID: 16800161 Review.
-
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.Pharmacoeconomics. 2006;24 Suppl 1:49-59. doi: 10.2165/00019053-200624001-00005. Pharmacoeconomics. 2006. PMID: 16800162 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
